Zobrazeno 1 - 10
of 15
pro vyhledávání: '"E Andresciani"'
Autor:
N Monti Guarnieri, B Fabrizzi, E Andresciani, AMF Garzone, S Bagagiolo, I Bartolucci, S Guglielmi, C Capone, C Polidori, A Pompilio
Publikováno v:
Section 4: Clinical pharmacy services.
Autor:
I Bartolucci, N Monti Guarnieri, AMF Garzone, E Andresciani, S Bagagiolo, E Cocci, C Polidori, A Pompilio
Publikováno v:
Section 5: Patient safety and quality assurance.
Autor:
GB Ortenzi, A. Simonini, E. Murrja, Amf Garzone, R. Sentinelli, E Andresciani, S. Pelliccioni, A Pompilio
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Kawasaki disease (KD) is a systemic vasculitis of unknown aetiology that affects children younger than 5 years old. The SARS-CoV-2 COVID pandemic highlighted cases reported to have an association between SARS-CoV-2 infection
Publikováno v:
Section 5: Patient Safety and Quality assurance.
Background and importance Cannabis based therapies have been used to treat epilepsy for millennia, but in the past few years several studies have led to the marketing in Europe of a drug based on cannabidiol with an indication for Lennox–Gastaut an
Autor:
Demeo, G Palmas, Amf Garzone, GB Ortenzi, A Pompilio, MA Berardi, Carlo Polidori, S Guglielmi, S Siliquini, L Porfiri, E Andresciani
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Nusinersen is an innovative drug given by intrathecal injection and used to treat 5q-spinal muscular atrophy (SMA), a severe neuromuscular disorder due to a defect in the survival motor neuron 1 (SMN1) gene. This antisense o
Autor:
MA Berardi, GB Ortenzi, A Pompilio, E Andresciani, M Vallorani, L Cingolani, Simona Gatti, Carlo Catassi, Amf Garzone, V Moretti, S Leoni
Publikováno v:
Eur J Hosp Pharm
Background A 7 month child with an unremarkable previous medical history presented with a history of 18 days of severe secretory diarrhoea. Clinical and histological features were consistent with autoimmune enteropathy. The patient could not tolerate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::207c47a4303f0c2f94536257f72c2cb7
https://europepmc.org/articles/PMC7535280/
https://europepmc.org/articles/PMC7535280/
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
V Carnielli, Carlo Polidori, V Moretti, E Andresciani, De Meo, F Ciuccarelli, Amf Garzone, A Pompilio, L Carloni, S Savini
Publikováno v:
European Journal of Hospital Pharmacy. 22:A27.2-A27
Background Intravenous (IV) drug treatment of preterm neonates is affected by: clinical status (i.e. sepsis/infections, immature physiology, pharmacokinetic/pharmacodynamic variation), shortage of ready-to-use formulations, small doses of drug requir
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
D Marravalle, Amf Garzone, V Moretti, A Mannucci, E Andresciani, A Ficcadenti, De Meo, F Ciuccarelli, A Pompilio
Publikováno v:
European Journal of Hospital Pharmacy. 21:A19.2-A19
Background There are almost 8,000 rare diseases (RD) (80% are genetically based) and 50% of them affect children. They are often highly complex metabolic diseases (MD): factors include heterogeneity (age of occurrence, aetiopathogenesis and symptomat